Physician profile
Lisa A Post
NPI 1508848623
$573.91
in general payments reported to CMS, 2019-2025
15 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $46.90 · 2023: $49.02 · 2024: $279 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $527.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $138.80 | 2023-2024 | |
| Novo Nordisk INC | $124.80 | 2024-2025 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $51.14 | 2025 | |
| Lilly USA, LLC | $30.92 | 2024 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $30.71 | 2025 | |
| Smith+Nephew, INC. | $29.04 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $24.95 | 2025 | Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.50 | 2025 | Caplyta |
| Exact Sciences Corporation | $18.54 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $18.36 | 2024 | Trelegy Ellipta |
| Kerecis Limited | $18.25 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Hydrofera LLC | $17.86 | 2022 | |
| Paratek Pharmaceuticals, INC. | $16.68 | 2024 | Nuzyra |
| Pfizer INC. | $16.10 | 2024 | |
| Tactile Systems Technology INC | $14.26 | 2023 | Entre Plus, Flexitouch Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Post listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.